Here’s a shocking truth: while the FTSE 100 flirts with record highs, a silent crisis is unfolding in one corner of the market—a phenomenon dubbed the “Claude crash.” But what exactly is it, and why should you care? It’s the moment when AI threatens to upend some of the UK’s most reliable, data-driven giants, and Relx, the former Reed Elsevier, is right in the eye of the storm. But here’s where it gets controversial: Is this the beginning of the end for these companies, or is the market overreacting? Let’s dive in.
The “Claude crash” gets its name from Anthropic’s AI tool, Claude, which recently introduced legal plug-ins that sent shockwaves through the market. The panic isn’t just about Relx—companies like the London Stock Exchange Group, Experian, Sage, and Informa are also feeling the heat. These firms dominate the unglamorous but lucrative world of data and analytics, and suddenly, their future looks uncertain. And this is the part most people miss: Relx, with its brands like The Lancet and LexisNexis, isn’t just another player—it’s a powerhouse that saw its shares soar from £5 in 2012 to £41 last year, valuing it at a staggering £70 billion.
Fast forward to today, and Relx’s shares have halved since their peak. The market’s fear? That AI will obliterate its impressive 34% profit margin. But is this fear justified? Relx’s recent full-year results suggest otherwise. Revenues climbed 7% to £9.6 billion, operating profits rose 9% to £3.3 billion, and the company even hiked its dividend by 7%. Plus, it announced a bigger share buyback of £2.25 billion—a move that screams confidence.
CEO Erik Engström argues that AI isn’t a threat but a key driver of growth. Here’s his logic: Relx operates in a niche market, providing must-have, court-reliable information that’s impossible to replicate. Sure, some of its data is public or licensed, but the real value lies in the decades of judgments, inferences, and interpretations baked into its offerings. AI, he says, will either enhance this value or make it more accessible to customers. Bold claim, right? But is he overlooking the potential for AI to commoditize their services? That’s the million-dollar question.
Relx also has another ace up its sleeve: it can strike licensing deals with AI firms or launch its own workflow tools without giving up its proprietary data. But here’s the kicker: If AI truly revolutionizes the industry, can Relx’s “competitive moat”—its unique advantage—really withstand the flood? The market’s 2% share price bounce after the results suggests lingering doubts.
So, what’s the smart move for Relx? Double down on share buybacks. With shares trading at half their price from a year ago, buying back 6% of its equity base this year alone could supercharge earnings per share—if, and it’s a big if, the company’s growth projections hold up. Activist investor Elliott Management is pushing for the same strategy at LSEG, another AI-rattled firm. But is this just a band-aid solution, or a masterstroke?
Here’s the real question for you: Is Relx’s confidence in its AI-proof business model justified, or is the market’s fear of the unknown warranted? Will share buybacks be enough to weather the storm, or is this just the calm before the AI tsunami? Let’s hear your thoughts in the comments—this debate is far from over.
